United States Patent 11,045,460: Arimoclomol Patent Scope, Claims, Expiration and NPC Market Exclusivity
U.S. Patent No. 11,045,460 protects the oral use of arimoclomol to treat Niemann-Pick disease type C, including dose ranges and certain combination regimens. The patent does not claim arimoclomol as a chemical compound, a specific capsule or granule formulation, or a manufacturing process. Its principal commercial value is a method-of-use barrier to generic arimoclomol products used for NPC.
The patent is assigned to Orphazyme A/S, the original developer of arimoclomol. Zevra Therapeutics commercializes arimoclomol as MIPLYFFA, approved by the FDA in September 2024 for NPC in patients aged 2 years and older, in combination with miglustat [1].
What does U.S. Patent 11,045,460 protect?
The patent claims a treatment method requiring four core elements:
- A human patient.
- Niemann-Pick disease type C.
- Oral administration.
- Arimoclomol or a pharmaceutically acceptable salt.
Claim 1 is the broadest independent claim:
“A method for treating Niemann-Pick disease Type C (NPC) in a human comprising orally administering arimoclomol, or a pharmaceutically acceptable salt thereof, to the human.”
The claim is disease-specific and route-specific. It does not require:
- A particular NPC genotype;
- A particular age;
- A particular disease stage;
- A specific arimoclomol salt;
- A specific formulation;
- A defined treatment duration;
- A response threshold;
- Concomitant miglustat;
- Enzyme replacement therapy; or
- A specific dose, unless the dependent claims are asserted.
A generic product marketed for oral arimoclomol treatment of NPC would face the strongest infringement risk if its proposed label expressly instructs treatment of NPC. Direct use by patients or physicians may also create infringement issues, but the commercial enforcement focus for a generic would ordinarily be the ANDA product, label, and induced-use theory.
How do the five claims differ?
| Claim |
Protected subject matter |
Additional limitation |
| 1 |
Oral arimoclomol treatment of human NPC |
No specific dose or combination therapy |
| 2 |
Claim 1 treatment method |
Daily dose of about 1 microgram/kg to about 100 mg/kg |
| 3 |
Claim 2 treatment method |
Concomitant administration of miglustat |
| 4 |
Claim 2 treatment method |
Concomitant enzyme replacement therapy |
| 5 |
Claim 4 treatment method |
Enzyme replacement is imiglucerase, agalsidase beta, or agalsidase alpha |
Claim 1 provides the main exclusionary position. Claims 2 through 5 add narrower fallback positions. A challenger that defeats claim 1 may still face claims 2 through 5 if its product or label falls within the dose or combination limitations.
The dose range in claim 2 is exceptionally broad. It extends from approximately 1 microgram/kg/day to approximately 100 mg/kg/day. That range covers ordinary therapeutic dosing and gives the patent substantial overlap with clinically relevant dosing regimens.
What is the technical scope of the arimoclomol claims?
Arimoclomol is a small-molecule heat-shock-protein co-inducer. In NPC, the claimed treatment is directed to a lysosomal storage disorder involving intracellular lipid trafficking and cholesterol accumulation.
The claims do not require a particular mechanism of action. A defendant generally could not avoid claim 1 merely by characterizing arimoclomol as acting through a different biological pathway, provided the product is orally administered to treat NPC.
The claims also do not require miglustat. Miglustat appears only in claim 3. This distinction matters because MIPLYFFA is approved for use with miglustat, while claim 1 independently covers oral arimoclomol treatment of NPC.
Claim construction issues
Potential claim-construction disputes include:
- Whether “treating” requires measurable clinical improvement or includes slowing progression;
- Whether an FDA label that identifies NPC treatment is enough to establish induced infringement;
- The meaning of “about” in the dose range;
- Whether a salt administered orally falls within “arimoclomol, or a pharmaceutically acceptable salt thereof”;
- Whether combination therapy under claims 3 through 5 requires simultaneous administration or permits sequential administration.
The absence of a defined response threshold makes “treating” potentially broad. A challenger would likely focus on written description, enablement, anticipation, obviousness, and the legal meaning of the treatment limitation.
When does U.S. Patent 11,045,460 expire?
The patent issued on June 29, 2021. Public patent records identify an April 15, 2010 priority date and an expected patent-term endpoint in April 2030, subject to any applicable patent-term adjustment, terminal disclaimer, or regulatory extension [2].
| Event |
Date |
| Earliest identified priority date |
April 15, 2010 |
| U.S. patent grant |
June 29, 2021 |
| Expected ordinary patent-term endpoint |
Approximately April 15, 2030 |
| FDA approval of MIPLYFFA |
September 20, 2024 |
| Expected FDA orphan exclusivity endpoint |
September 20, 2031, subject to statutory conditions |
The precise operative expiration date should be taken from the USPTO patent record and the current FDA Orange Book entry. Patent expiration and FDA orphan-drug exclusivity are separate rights. The patent may expire before orphan exclusivity ends.
What is the Orange Book status of arimoclomol and MIPLYFFA?
The FDA approved MIPLYFFA, containing arimoclomol, for treatment of NPC in adults and pediatric patients aged 2 years and older, in combination with miglustat [1].
The relevant regulatory protections are:
| Protection |
Status and commercial effect |
| FDA approval |
MIPLYFFA approved for NPC in patients aged 2 years and older |
| Orphan-drug exclusivity |
Seven years from approval for the approved NPC indication, subject to statutory exceptions |
| U.S. patent |
U.S. Patent 11,045,460 covers oral arimoclomol treatment methods |
| Orange Book relevance |
Method-of-use patent listing can require a Paragraph IV certification or a section viii statement, depending on the proposed labeling |
| Pediatric exclusivity |
No separate six-month pediatric extension should be assumed without a confirmed FDA grant |
| Biosimilar pathway |
Not applicable because arimoclomol is a small molecule |
The Orange Book analysis is label-dependent. A generic applicant that seeks approval for the NPC indication would confront the listed method-of-use patent and would likely need to certify under Paragraph IV if it contends that the patent is invalid, unenforceable, or not infringed.
A section viii statement could be relevant only if the generic label omits the patented NPC use and retains only non-patented uses. That strategy has limited commercial value if NPC is the only commercially viable indication for arimoclomol.
What Paragraph IV challenges and generic entry risks exist?
A generic applicant could challenge U.S. Patent 11,045,460 through an ANDA Paragraph IV certification. The principal invalidity theories would likely be:
Anticipation
The challenger would need prior art disclosing oral arimoclomol treatment of human NPC. General disclosures of arimoclomol for unrelated diseases would not necessarily anticipate claim 1.
Obviousness
The challenger could argue that the claimed use was obvious based on:
- Prior arimoclomol pharmacology;
- NPC disease biology;
- Heat-shock-protein or lysosomal-storage-disorder literature;
- Earlier clinical or preclinical work;
- A reasonable expectation that arimoclomol would treat NPC.
The strongest defense would likely rely on the disease-specific clinical results and the unpredictability of translating a stress-response modulator into an effective NPC treatment.
Written description and enablement
Claim 1 covers oral arimoclomol treatment broadly across human NPC patients. A challenger could argue that the specification does not adequately support the full scope of the patient population or enable treatment without undue experimentation.
Claims 3 through 5 may face narrower written-description questions because they cover combinations with miglustat and enzyme replacement therapies, including therapies principally associated with other lysosomal disorders.
Infringement
Claim 1 creates the greatest generic-entry risk because it does not require miglustat or a narrow dosage. A generic label that instructs oral arimoclomol treatment for NPC would likely be drafted with the patent in mind.
A successful Paragraph IV filing could trigger 45-day litigation by the patent owner and a potential 30-month FDA approval stay under the Hatch-Waxman framework [3]. The timing depends on the date of notice and whether litigation is filed.
What formulations are protected by U.S. Patent 11,045,460?
The patent claims do not expressly require a formulation. They cover oral administration of arimoclomol or a pharmaceutically acceptable salt, regardless of whether the product is supplied as:
- A capsule;
- An oral granule;
- A powder for administration;
- A tablet; or
- Another orally administered dosage form.
The patent therefore has broad use coverage but limited formulation specificity. A competitor could potentially design around a formulation patent, but it would not avoid claim 1 merely by changing capsule materials, excipients, particle size, or packaging.
Conversely, a formulation patent would provide a separate layer of protection if it claims a specific arimoclomol composition, release profile, particle structure, salt, or manufacturing process.
Does the patent cover miglustat combination therapy?
Yes, but only through claim 3. Claim 3 depends on claim 2, so it requires:
- Oral arimoclomol treatment of NPC;
- The claimed daily dose range; and
- Administration of miglustat.
This claim closely tracks the FDA-approved MIPLYFFA treatment context. It is narrower than claim 1 because a product or regimen outside the dose range could avoid claim 3 while still potentially infringing claim 1.
The combination claim may have commercial importance even if claim 1 is challenged. It gives the patent owner a second infringement theory directed at the approved combination regimen.
Does the patent cover enzyme replacement therapy combinations?
Claims 4 and 5 cover arimoclomol treatment combined with enzyme replacement therapy.
Claim 5 identifies:
- Imiglucerase;
- Agalsidase beta; or
- Agalsidase alpha.
These enzymes are associated principally with Gaucher disease and Fabry disease treatment rather than standard NPC therapy. Their inclusion broadens the patent’s combination-therapy coverage but may have limited direct relevance to the current MIPLYFFA label.
Claims 4 and 5 require the daily dose limitation through dependency on claim 2. They are therefore narrower than claim 1 and claim 3.
How strong is the patent estate for arimoclomol?
The estate has a strong method-of-use position for the approved NPC indication but appears less comprehensive than a portfolio combining compound, formulation, manufacturing, dosing, and combination patents.
| Protection category |
Position of U.S. Patent 11,045,460 |
| Chemical compound |
Not claimed in the quoted claims |
| Oral NPC treatment |
Strong central coverage through claim 1 |
| Dose range |
Broad coverage through claim 2 |
| Miglustat combination |
Covered by claim 3 |
| Enzyme replacement combinations |
Covered by claims 4 and 5 |
| Specific formulation |
Not required by the quoted claims |
| Manufacturing process |
Not claimed in the quoted claims |
| Genotype-specific treatment |
Not required |
| Age-specific treatment |
Not required |
| Disease-stage limitation |
Not required |
The patent’s main weakness is concentration in method claims. Method claims can be commercially powerful when the approved indication is narrow and the product has no established alternative use. They can be less durable if a generic can obtain approval without the patented indication or if the claims are invalidated.
Which companies are challenging arimoclomol exclusivity?
The commercial competition is more likely to arise from generic-drug manufacturers than from biosimilar developers. Arimoclomol is a small molecule, so the relevant pathway is an ANDA, not a biosimilar application under section 351(k) of the Public Health Service Act.
No publicly documented Paragraph IV challenger or federal patent litigation affecting U.S. Patent 11,045,460 is identified in the cited FDA and patent records. The absence of a reported challenge does not eliminate future risk. The economic incentive to challenge depends on MIPLYFFA sales, the remaining patent term, orphan exclusivity, manufacturing complexity, and the availability of a commercially viable skinny-label strategy.
What generic launch scenarios exist?
Launch after patent expiration
A generic could launch after the patent expires, subject to the remaining orphan exclusivity and any other listed patents. If orphan exclusivity remains in force, FDA approval for the same NPC indication could still be blocked even after patent expiry.
Paragraph IV launch
A challenger could certify that the patent is invalid, unenforceable, or not infringed. Litigation could delay approval for up to 30 months, unless the case is resolved earlier or the stay is modified.
Section viii launch
A generic could omit the patented NPC indication if FDA-approved non-patented uses exist. This pathway is commercially weak if NPC is the principal or exclusive approved use.
Authorized generic or settlement launch
The patent owner could settle litigation by granting a future entry date, an authorized-generic arrangement, or a license. No publicly documented settlement involving this patent is identified in the cited records.
What patent litigation affects arimoclomol?
The relevant litigation risk is Hatch-Waxman litigation over the listed method-of-use patent. The expected triggers are:
- An ANDA filing with a Paragraph IV certification;
- Notice to the patent owner and NDA holder;
- A 45-day period for filing suit;
- A potential 30-month stay;
- Claim-construction and validity proceedings in federal district court.
The patent owner could seek an injunction, damages, or a judgment that the generic product’s label induces infringement. The generic applicant would likely challenge claim scope, validity, and the relationship between the approved label and the patented use.
What is the revenue exposure from the patent?
The patent’s commercial exposure is concentrated in MIPLYFFA revenue from NPC. Orphan-drug economics can support premium pricing, but the addressable population is small. Revenue risk is therefore driven more by exclusivity duration and reimbursement than by broad population volume.
The principal loss-of-exclusivity event is not a single date. It is the earliest commercially effective date produced by:
- Patent expiry;
- Expiry of orphan-drug exclusivity;
- Resolution of Paragraph IV litigation;
- A licensed generic entry;
- FDA approval of a competing therapy; or
- Reimbursement and market-access pressure.
On the stated records, the patent could remain relevant through approximately April 2030, while orphan exclusivity may extend to approximately September 2031 for the approved NPC indication.
Key Takeaways
- U.S. Patent 11,045,460 is a method-of-use patent directed to oral arimoclomol treatment of human NPC.
- Claim 1 is the central commercial claim and does not require miglustat, enzyme replacement therapy, a specific age, genotype, or dose.
- Claim 2 covers a broad daily dosage range of approximately 1 microgram/kg to 100 mg/kg.
- Claim 3 covers arimoclomol combined with miglustat, subject to the claim 2 dose limitation.
- Claims 4 and 5 cover combinations with specified enzyme replacement therapies.
- The patent does not, based on the quoted claims, protect arimoclomol’s chemical structure, a particular formulation, or manufacturing process.
- The expected patent-term endpoint is approximately April 15, 2030, subject to the official USPTO term calculation.
- MIPLYFFA received FDA approval in September 2024 for NPC in patients aged 2 years and older, in combination with miglustat.
- Orphan-drug exclusivity may extend beyond the patent into September 2031.
- Generic applicants would likely face a Paragraph IV strategy if they seek the NPC indication.
- Arimoclomol is a small molecule, so biosimilar competition is not the relevant risk. The relevant pathway is generic ANDA competition.
FAQs About U.S. Patent 11,045,460 and Arimoclomol
Can a generic arimoclomol product avoid U.S. Patent 11,045,460 by using a different dose?
Possibly for claims 2 through 5, but not necessarily for claim 1. Claim 1 does not state a specific dose. A different dose could avoid the dependent dose and combination claims while still falling within the broad oral-treatment claim.
Does claim 1 require treatment with miglustat?
No. Miglustat is required only by claim 3. Claim 1 covers oral arimoclomol treatment of NPC without requiring combination therapy.
Does U.S. Patent 11,045,460 cover intravenous arimoclomol?
The quoted claims require oral administration. Intravenous administration would not satisfy the express route limitation in claim 1.
Can a generic receive approval for a non-NPC use before the patent expires?
Potentially, if FDA recognizes a non-patented use and the generic label omits the patented NPC indication. The commercial value of that strategy depends on whether a viable non-NPC market exists.
Is MIPLYFFA protected by biosimilar exclusivity?
No. Arimoclomol is a small-molecule drug. MIPLYFFA is subject to small-molecule generic competition under the ANDA framework, not biosimilar competition under section 351(k).
References
-
U.S. Food and Drug Administration. (2024). MIPLYFFA (arimoclomol) prescribing information. FDA.
-
United States Patent and Trademark Office. (2021). U.S. Patent No. 11,045,460, Methods of treating Niemann-Pick disease type C. USPTO Patent Center.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: MIPLYFFA application and approval information. FDA.
-
U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity provisions. FDA.